Moderna (MRNA) stock falls for a seventh session, the longest losing streak since November 2024, as analysts cite valuation concerns after the YTD rally. Read more here.
Detailed price information for Moderna Inc (MRNA-Q) from The Globe and Mail including charting and trades.
The healthcare stock has hit multi-year highs this year amid positive results from its personalized cancer vaccine.
Josh Brown and Sean Russo break down what's going on with these stocks.
2026-11-13. The following slide deck was published by Moderna, Inc.
Look at the promising data for Moderna and Merck’s experimental cancer vaccine and the research suggesting the shingles vaccine can delay dementia.
Stéphane Bancel, Moderna CEO, joins 'Mad Money' host Jim Cramer to talk its partnership with Merck on a cancer treatment, expanding beyond vaccines, clinical trial data, and more.
Moderna, led by CEO Stéphane Bancel, is forging the future of mRNA with its new personalized cancer vaccine.
Moderna promised 20% sales growth in 2026 -- but Wall Street wants 24%.
Moderna plans to reinvest in its pipeline, particularly oncology treatments like its personalized cancer vaccine. But investors are keeping their eye on rising spending.
MSCI's November 2026 review adds Moderna to the World Index and 10 stocks to its U.S. Prime Market 750, removing eight after Nov.
Revenue for the vaccine maker rose sharply in the third quarter, but it was largely due to COVID sales, which have been down significantly over the past five years.
Moderna’s revenue growth also reflects revenue from international vaccine partnerships and the brightening US policy outlook.
This is the newest page. Registered accounts read further back.